Do you want to read an article? Please log in or register.
Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study
Heart Failure
Related content
Heart Failure
Cost-effectiveness of sacubitril/valsartan in chronic heart-failure patients with reduced ejection fraction
Swiss Med Wkly.
Ademi Z, Pfeil AM, Hancock E, Trueman D, Haroun RH, Deschaseaux C, Schwenkglenks M
doi: 10.4414/smw.2017.14533.
Heart Failure
Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial
JAMA.
Desai AS, Solomon SD, Shah AM, Claggett BL, Fang JC, Izzo J, McCague K, Abbas CA, Rocha R, Mitchell GF, EVALUATE-HF Investigators.
doi: 10.1001/jama.2019.12843.
Heart Failure
Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction
JAMA.
Januzzi JL Jr, Prescott MF, Butler J, Felker GM, Maisel AS, McCague K, Camacho A, Piña IL, Rocha RA, Shah AM, Williamson KM, Solomon SD, PROVE-HF Investigators.
doi: 10.1001/jama.2019.12821.
Heart Failure
The safety of sacubitril-valsartan for the treatment of chronic heart failure.
Expert Opin Drug Saf.
Tyler JM, Teerlink JR
doi: 10.1080/14740338.2017.
Heart Failure
Effect of Neprilysin Inhibition on Various Natriuretic Peptide Assays
J Am Coll Cardiol.
Ibrahim NE, McCarthy CP, Shrestha S, Gaggin HK, Mukai R, Szymonifka J, Apple FS, Burnett JC Jr, Iyer S,
Januzzi JL Jr
doi: 10.1016/j.jacc.
RECOMMENDED
Heart Failure
Effects of Sacubitril-Valsartan, versus Valsartan, in Women Compared to Men with Heart Failure and Preserved Ejection Fraction: Insights from PARAGON-HF
★ 3
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
Circulation.
McMurray JJV, Jackson AM, Lam CSP, Redfield MM, Anand IS, Ge J, Lefkowitz MP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Rizkala AR, Sabarwal SV, Shah AM, Shah SJ, Shi VC, van Veldhuisen DJ, Zannad F, Zile MR, Cikes M, Goncalvesova E, Katova T, Kosztin A, Lelonek M, Sweitzer NK, Vardeny O, Claggett B, Jhund PS, Solomon SD
doi: 10.1161/CIRCULATIONAHA.119.044491.
Heart Failure
Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial
JAMA Cardiol.
Chandra A, Lewis EF, Claggett BL, Desai AS, Packer M, Zile MR, Swedberg K, Rouleau JL, Shi VC, Lefkowitz MP, Katova T, McMurray JJV, Solomon SD
doi: 10.1001/jamacardio.
RECOMMENDED
Heart Failure
Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction
doi: 10.1016/j.jchf.2020.03.002.
Heart Failure
B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial
J Am Coll Cardiol.
Myhre PL, Vaduganathan M, Claggett B, Packer M, Desai AS, Rouleau JL, Zile MR, Swedberg K, Lefkowitz M, Shi V, McMurray JJV, Solomon SD
doi: 10.1016/j.jacc.2019.01.018.